Vivet Therapeutics gene therapy for Wilson disease

Bernard Benichou, MD, PhD
Chief Medical Officer, Vivet
Dr. Benichou shares updates about Vivet’s ongoing GATEWAY gene therapy clinical trial.
Administered as a single intravenous infusion, trial participants are given a corrective version (VTX-801) of the malfunctioning ATP7B gene.
Currently, there are 10 sites in the United States and Europe participating. Dr. Benichou updates progress on the clinical trial including its safety, efficacy and durability.
For more information visit www.wilsondisease.org under News, Vivet Therapeutics Wilson Disease Gene Therapy Clinical Trial Update.